Purac to build new plant for biomedical resorbale polymers in the USA
10 September 2010. Back
Purac announces the investment in a new manufacturing
facility for its biomedical polymers. The plant is meant to support
the growing resorbable polymers business of Purac Biomaterials.
Purac currently operates a plant for biomedical polymers in The
Netherlands. This second facility will be built in the USA. The
investment for this new plant will be EUR 15 million. The
construction of the facility will start in 2011 and is expected to
be completed before the end of the year.
Arno van de Ven, Purac Vice President Chemicals & Pharma
comments: "This represents an important step in the
biomedical polymer business and shows Purac's continued commitment
to this market. It provides us with the capability to support the
growth of our existing and new business partners."
Besides an increase in the production capacity, the new facility
will bring Purac Biomaterials more flexibility and a more balanced
presence in its global markets".
Menno Lammers, Director of Purac Biomaterials comments: "As
an experienced supplier to pharmaceutical and medical device
companies, we understand the importance of guaranteed supply
continuity. Over the last years, the importance of risk management
has increased and with this facility we will be in the unique
position to provide our customers with dual sourcing".
The Purac Biomaterials business comprises Lactide based polymers
such as Poly Lactic Acid (PLA) and Lactide/Glycolide Copolymers
(PGLA). The technology as developed for Purac's biomedical polymers
also formed the basis for Purac's activities in L- and D-Lactides
for bioplastics such as Poly Lactic Acid (PLA).